Machelle Sanders net worth and biography

Machelle Sanders Biography and Net Worth

Machelle Sanders was appointed to the Board of directors in February 2022. She currently serves as North Carolina Secretary of Commerce. Ms. Sanders has over 30 years of pharmaceutical and biotechnology experience with increasing levels of quality assurance and manufacturing operations responsibilities with Biogen, Purdue Pharmaceuticals, and AkzoNobel. Most recently, she was the Product Operation Lead for Biogen’s $8 billion multiple sclerosis franchise and was Vice President of manufacturing and General Manager for Biogen’s 1200-employee Research Triangle Park facility, the company’s largest global manufacturing operation. Prior to being appointed as North Carolina’s Secretary of Commerce in February 2021, Ms. Sanders served as Secretary of the North Carolina Department of Administration from January 2017 until February 2021. Ms. Sanders currently serves on the board of directors of Fortrea. She received a B.S. in biochemistry from North Carolina State University and a Master’s in health administration from Pfeiffer University.

What is Machelle Sanders' net worth?: The estimated net worth of Machelle Sanders is at least $206,123.06 as of June 17th, 2024. Ms. Sanders owns 27,742 shares of BioCryst Pharmaceuticals stock worth more than $206,123 as of April 3rd. This net worth estimate does not reflect any other assets that Ms. Sanders may own. Learn More about Machelle Sanders' net worth.
How do I contact Machelle Sanders?: The corporate mailing address for Ms. Sanders and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at investorrelations@biocryst.com. Learn More on Machelle Sanders' contact information.
Has Machelle Sanders been buying or selling shares of BioCryst Pharmaceuticals?: Machelle Sanders has not been actively trading shares of BioCryst Pharmaceuticals within the last three months. Most recently, Machelle Sanders sold 4,689 shares of the business's stock in a transaction on Monday, June 17th. The shares were sold at an average price of $6.00, for a transaction totalling $28,134.00. Following the completion of the sale, the director now directly owns 27,742 shares of the company's stock, valued at $166,452. Learn More on Machelle Sanders' trading history.
Who are BioCryst Pharmaceuticals' active insiders?: BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Steve Aselage (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Steven Galson (Director), Nancy Hutson (Director), Alan Levin (Director), Amy McKee (Director), Vincent Milano (Director), Machelle Sanders (Director), William Sheridan (Insider), Jon Stonehouse (CEO), and Helen Thackray (Chief Research & Development Officer). Learn More on BioCryst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of BioCryst Pharmaceuticals?: During the last twelve months, BioCryst Pharmaceuticals insiders bought shares 6 times. They purchased a total of 103,601 shares worth more than $596,337.56. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 13,289 shares worth more than $82,486.00. The most recent insider tranaction occured on June, 24th when Director Amy E Mckee sold 8,600 shares worth more than $54,352.00. Insiders at BioCryst Pharmaceuticals own 4.8% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.
Information on this page was last updated on 6/24/2024.

Machelle Sanders Insider Trading History at BioCryst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/17/2024	Sell	4,689	$6.00	$28,134.00	27,742
6/15/2023	Sell	4,000	$7.98	$31,920.00	25,611

Machelle Sanders Buying and Selling Activity at BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Today's Range

Now: $7.43

$7.15

$7.44

50 Day Range

MA: $8.17

$7.25

$9.39

2 Week Range

Now: $7.43

$4.03

$9.50

Volume

2,223,517 shs

Average Volume

2,760,443 shs

Market Capitalization

$1.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84